Cannabis based medicines group GW Pharmaceuticals has had its Sativex treatment for the relief of spasticity in Multiple Sclerosis (MS) approved by the New Zealand regulatory authority.

The mouth spray, which contains two cannabinoids or active ingredients - THC and CBD - is the first cannabinoid medicine derived from whole plant extracts from the cannabis sativa plant...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... geid/1814/

A Cannabis-based drug that may relieve symptoms of multiple sclerosis will be denied to Calderdale patients.

NHS Calderdale has confirmed the oral spray Sativex will not be routinely funded for the area's estimated 300 sufferers.

The newly-licensed medicine contains cannabinoids...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814

Almirall, S.A. and GW Pharmaceuticals plc today announced that the health authorities in Spain have granted regulatory approval for Sativex® Oromucosal Spray as an add-on therapy for the treatment of moderate to severe spasticity due to Multiple Sclerosis (MS) in patients who have not responded adequately to other anti-spasticity medication.

Prior to launch, Sativex® requires pricing and reimbursement approval from the Spanish Ministry of Health. This final approval process is expected to be completed ...

A Birkdale mum, with multiple sclerosis, has hailed a new drug containing cannabis for easing the symptoms of her condition.

Fiona Caplan, 51, first tried out the medicine, Sativex, five months ago and found it aided her movements by relieving the stiffness in her legs.

The mother-of-one had to buy the drug privately as it was not available on the NHS, but now Sativex has been granted a license on the NHS and may ...

Abstract

OBJECTIVE: To determine the efficacy of Sativex (USAN: nabiximols) in the alleviation of spasticity in people with multiple sclerosis.

METHODS: The results from three randomized, placebo-controlled, double-blind parallel group studies were combined for analysis.

PATIENTS: 666 patients with multiple sclerosis and spasticity....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814

GW Pharmaceuticals Plc's (GWP.L) cannabis-derived medicine Sativex has been approved in Britain for treating spasticity in patients with multiple sclerosis, in a landmark decision for the small drugmaker.

The much-delayed product was finally granted a British licence on Thursday, an official from the Medicines and Healthcare products Regulatory Agency (MHRA) told Reuters on Friday.

The company later issued a statement confirming the move.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814 ...

First time I heard of this but if it works it gets a thumbs up from me.

<shortened url>

I have heard that Sativex is working great for Neuropathic pain. Does anyone have information on the status of drug trials here in the US? Has anyone tried this drug? If so what was your experience? Does anyone know how I could get this drug?

Thank you for any information you can provide.

Fighter of MS
Suwanee, GA

Cannabis-based Multiple Sclerosis drug, Sativex, shows long-term efficacy
08 September 2008

GW Pharmaceuticals Plc announced today that a study of its cannabis-based pain killer Sativex has shown long-term efficacy in the treatment of neuropathic pain due to multiple sclerosis.

It is the first time that the long-term effectiveness of the drug had been demonstrated in a so-called placebo-controlled study, where it is tested against a dummy drug.

The news is also significant for the company ...

Somewhat bad news...



GW plunges as cannabis drug delayed in Europe

July 20, 2007 -- Reuters -- Britain's GW Pharmaceuticals announced a new delay for its pioneering cannabis-based medicine on Friday, saying European drug regulators had requested a further clinical study as a condition for approval.

Shares in GW, which has dispensation from the British government to use cannabis for medical research, plunged around a third in value as Chief Executive Justin Gover said the ...